Developing new carbon-based agents to enhance radiation therapy for cancer treatment
The development of novel radiation-sensitizer based on ultra-small carbon dots
This study is exploring a new way to make radiation therapy work better for people with non-small cell lung cancer by using tiny carbon dots that could help kill cancer cells while causing fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10854795 on NIH RePORTER |
What this research studies
This research focuses on creating a novel type of radiation-sensitizer using ultra-small carbon dots to improve the effectiveness of radiation therapy for patients with non-small cell lung carcinoma (NSCLC). The approach aims to enhance the cancer-killing effects of radiation while minimizing systemic toxicity, which is a common issue with traditional sensitizers. By utilizing the unique properties of these carbon dots, the research seeks to overcome the challenges of radioresistance in cancer treatment. Patients may benefit from improved treatment outcomes with fewer side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung carcinoma who are undergoing radiation therapy.
Not a fit: Patients with cancers other than non-small cell lung carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective radiation treatments for cancer patients with reduced side effects.
How similar studies have performed: Previous research has shown promise in using novel sensitizers to enhance radiation therapy, indicating potential for success in this approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Li, Zibo — Univ of North Carolina Chapel Hill
- Study coordinator: Li, Zibo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.